annual meeting program - American Society of Clinical Oncology

1:00 PM - 4:00 PM
ORAL ABSTRACT SESSION
Melanoma/Skin Cancers
Location: S406 (Vista Room)
CME credit: 3
Track(s): Melanoma/Skin Cancers
Saturday, June 5, 2010
Tim Eisen, PhD, FRCP—Co-Chair
University of Cambridge/Cancer Research UK
Thomas Gajewski, MD, PhD—Co-Chair
The University of Chicago
1:00 PM E4697: Phase III cooperative group study of yeast-derived granulocyte
macrophage colony-stimulating factor (GM-CSF) versus placebo as adjuvant
treatment of patients with completely resected stage III-IV melanoma.
(Abstract #8504)
D. H. Lawson, S. J. Lee, A. A. Tarhini, K. A. Margolin, M. S. Ernstoff,
J. M. Kirkwood
1:15 PM Randomized phase III trial comparing postoperative adjuvant ganglioside
GM2-KLH/QS-21 vaccination versus observation in stage II (T3-T4N0M0)
melanoma: Final results of study EORTC 18961. (Abstract #8505)
A. M. Eggermont, S. Suciu, P. Rutkowski, J. Marsden, A. Testori, P. Corrie,
S. Aamdal, P. A. Ascierto, P. Patel, A. Spatz, EORTC Melanoma Group
1:30 PM Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus
low-dose interferon alfa-2b (18 months) in melanoma patients without
macro-metastatic nodes: EADO trial. (Abstract #LBA8506)
J. J. Grob, T. Jouary, B. Dreno, R. Gutzmer, A. Hauschild, M. T. Leccia, M.
Landthaler, J. Asselineau, C. Garbe, H. E. Pehamberger
Discussion
1:45 PM Michael S. Sabel, MD, FACS (Abstracts #8504–LBA8506)
University of Michigan
2:00 PM Interleukin-21 (IL-21) activity in patients (pts) with metastatic melanoma
(MM). (Abstract #8507)
T. M. Petrella, R. Tozer, K. Belanger, K. J. Savage, R. Wong, S. Kamel-Reid,
V. Tron, B. Chen, N. N. Hunder, E. A. Eisenhauer
2:15 PM First report of a randomized phase II trial of multi-epitope vaccination with
melanoma peptides for cytotoxic T cells and helper T cells in patients with
metastatic melanoma: An Eastern Cooperative Oncology Group study
(E1602). (Abstract #8508)
C. L. Slingluff, S. J. Lee, K. A. Chianese-Bullock, W. C. Olson, L. H. Butterfield,
P. D. Leming, J. M. Kirkwood
2:30 PM Re-induction with ipilimumab, gp100 peptide vaccine, or a combination of
both from a phase III, randomized, double-blind, multicenter study of
previously treated patients with unresectable stage III or IV melanoma.
(Abstract #8509)
F. S. Hodi, S. O’Day, D. F. McDermott, J. B. Haanen, C. Robert, X. Zhu,
M. J. Yellin, R. A. Ibrahim, A. Hoos, J. D. Wolchok
133
SATURDAY